CYP1B1 and neoplasm: Importantly, the clinical relevance of this axis is underscored by our findings that CYP1B1 knockdown restored sunitinib sensitivity in vivo and that combined CYP1B1 inhibition and sunitinib treatment yielded tumour suppression effects superior to those of monotherapy.